Linda Pissott Reig

Linda Pissott Reig focuses her practice on the life sciences industry. She has extensive experience with the laws and industry standards that apply to the marketing and sale of pharmaceuticals, medical devices, biologics, dietary supplements and medical foods.

Linda previously served as the co-chair for the firm’s FDA Section. She joined Buchanan Ingersoll & Rooney after having previously served as a principal for a New Jersey–based law firm, and Vice President, Compliance Services of its pharmaceutical services subsidiary.

Linda leads the Buchanan team that serves as legal counsel and strategic partner to the REMS Industry Consortium (RIC), a nonprofit organization that brings together the perspectives of organizations that sell, or anticipate selling, prescription drugs or biologics subject to Risk Evaluation and Mitigation Strategies (REMS). Buchanan advises on FDA Regulatory, Antitrust, Corporate, Governance, Insurance/Risk Management, Intellectual Property/Trademark and other issues, as well as strategy in advancing the RIC mission.

Linda counsels companies on lawful marketing and sale of FDA-regulated products. She reviews promotional materials (including broadcast ads, print materials, internet/social media) and guides other initiatives such as set-up and execution of physician speaker programs and best practices for collaboration with patient support groups. Linda also provides guidance on lawful preapproval communication strategies to companies awaiting FDA approval.

In addition, Linda advises on compliance with industry standards for clinical trial set-up and oversight, including recruitment of investigators and subjects.  She conducts compliance training for life sciences companies on compliance topics. Linda has also counseled life sciences companies on steps need to comply with privacy requirements, including the California Consumer Privacy Act.

She prepares Standard Operating Procedures and Policies for corporate compliance programs, negotiates and drafts agreements and advises on consulting arrangements with key opinion leaders. In addition, she advises on pharmacovigilance, advisory boards, continuing medical education grants, charitable contributions and labeling changes. Linda guides companies on how to minimize legal risk while achieving business objectives.

On the state law side, Linda assists companies with their state law obligations, such as aggregate spend, marketing disclosures, data-mining, clinical trial disclosure, adherence to compliance codes, sales representative licensure and manufacturing/distribution licensure.

Linda serves as co-chair of the BioNJ Legal, Compliance and Regulatory Advisory Committee, which she was instrumental in forming in 2008. The committee is comprised of in-house counsel and compliance representatives from top-ranking NJ-based biotechnology companies who discuss new legal developments and put together programs of interest to the NJ-based biotechnology community.

With her broad base of knowledge of the life sciences industry, Linda brings experience with state and federal laws, including:

• Patient Protection and Affordable Care Act of 2010
• Food & Drug Administration Modernization Act of 1997
• Food, Drug and Cosmetic Act
• Anti-Kickback Statute & False Claims Act

Before joining Buchanan, Linda worked as in-house counsel (while on secondment) for a pharmaceutical company part-time for five years.  While an associate, Linda litigated commercial disputes, as well as products liability/consumer fraud claims (both individual suits and class actions) arising from use of pharmaceuticals and medical devices.  She served as a judicial clerk for the Hon. Marie L. Garibaldi, the first woman justice appointed to the New Jersey Supreme Court.

Linda's relevant reported cases include:

• Thiedemann v. Mercedes–Benz USA, LLC, 183 N.J. 234, 872 A.2d 783 (2005)
• West Morris Pediatrics v. Henry Schein, Inc., 385 N.J. Super. 581, 897 A.2d 1140 (Law Div. 2004)
• Estate of Frankl v. Goodyear Tire & Rubber Co., 181 N.J. 1, 853 A.2d 880 (2004)
• Erny v. Estate of Merola, 171 N.J. 86, 792 A.2d 1208 (2002)

Linda authored chapters in the Practicing Law Institute's Pharmaceutical Compliance and Enforcement Answer Book 2023 entitled "Risk Evaluation and Mitigation Strategies (REMS) and Related Post-Market Safety Oversight" and "Impact of FDA Regulatory and Compliance Oversight on Product Liability Exposure of Pharmaceutical Manufacturers," (as well as prior year editions beginning in 2014/2015).

Linda has garnered an AV^® Preeminent certification from Martindale-Hubbell^® Peer Review Ratings, the highest available mark for professional excellence.  In 2007, Linda was recognized by the New Jersey Law Journal on its annual "40 Under 40" list.  She was also selected for inclusion on the 2006–2008 New Jersey Super Lawyers^® Rising Stars list, representing the top 2.5 percent of young attorneys practicing in New Jersey. In 2022, Linda was designated by NJBIZ as a “Leader in Law,” which recognizes law practitioners who have an outstanding dedication to their occupation and their communities. 

To learn more about industry rankings, click here.
No aspect of this advertisement has been approved by the Supreme Court of New Jersey.